National Institute on Drug Abuse

Funds addiction research in the United States through the National Institute on Drug Abuse and partner pathways spanning treatment and prevention solutions.

The National Institute on Drug Abuse, or NIDA, is the NIH institute focused on substance use and addiction research. It covers the path from basic neuroscience through clinical trials and health services, and its remit spans opioids, cannabis, stimulants, tobacco, and related drug harms. As part of the National Institutes of Health under the Department of Health and Human Services, it is the largest federal supporter of research in this field.

NIDA uses standard NIH mechanisms, including R01 and R21 grants, SBIR and STTR support for small businesses, the HEAL Initiative on opioids, the Clinical Trials Network, and special awards such as Avant-Garde and Avenir. The institute's SBIR and STTR cap reaches $3.4 million, which gives it real weight on translational and technology-driven work. Its named opportunities are rolling and span discovery, innovation, and advanced career paths.

NIDA is a strong fit for teams that can show relevance to addiction biology, treatment, prevention, or health services, especially when the work can move from mechanism to intervention. Proposals do best when they make the problem, the study design, and the expected impact clear in people or communities. Because the institute spans discovery and services, it can support projects that begin in the lab, the clinic, or implementation research.